Short Interest in NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Rises By 55.3%

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) saw a large increase in short interest in the month of January. As of January 30th, there was short interest totaling 76,711 shares, an increase of 55.3% from the January 15th total of 49,408 shares. Based on an average daily volume of 273,476 shares, the short-interest ratio is presently 0.3 days. Currently, 0.2% of the company’s shares are sold short. Currently, 0.2% of the company’s shares are sold short. Based on an average daily volume of 273,476 shares, the short-interest ratio is presently 0.3 days.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised shares of NeuroOne Medical Technologies from a “hold” rating to a “strong-buy” rating in a report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $2.23.

NeuroOne Medical Technologies Price Performance

Shares of NeuroOne Medical Technologies stock traded up $0.06 during trading hours on Monday, hitting $0.81. The company’s stock had a trading volume of 128,660 shares, compared to its average volume of 226,686. NeuroOne Medical Technologies has a 12 month low of $0.40 and a 12 month high of $1.25. The company has a market capitalization of $41.01 million, a PE ratio of -10.17 and a beta of 0.70. The stock has a 50 day moving average of $0.80 and a 200 day moving average of $0.80.

NeuroOne Medical Technologies (NASDAQ:NMTC) last announced its quarterly earnings results on Tuesday, December 16th. The company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.08. NeuroOne Medical Technologies had a negative net margin of 29.81% and a negative return on equity of 74.69%. The firm had revenue of $2.74 million for the quarter, compared to analyst estimates of $2.47 million. During the same quarter in the previous year, the firm posted ($0.46) earnings per share.

Institutional Investors Weigh In On NeuroOne Medical Technologies

Institutional investors have recently bought and sold shares of the company. Focus Financial Network Inc. acquired a new stake in shares of NeuroOne Medical Technologies in the third quarter valued at approximately $31,000. Warberg Asset Management LLC acquired a new position in shares of NeuroOne Medical Technologies during the 2nd quarter worth about $27,000. Legato Capital Management LLC bought a new position in shares of NeuroOne Medical Technologies in the 4th quarter valued at about $34,000. Squarepoint Ops LLC acquired a new stake in shares of NeuroOne Medical Technologies in the fourth quarter valued at about $36,000. Finally, Susquehanna International Group LLP bought a new stake in NeuroOne Medical Technologies during the third quarter worth about $47,000. Institutional investors own 16.07% of the company’s stock.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.